Vanguard National Trust
DNA icon

Vanguard National Trust’s Ginkgo Bioworks DNA Stock Holding History

Vanguard National Trust’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$61 – 798
2026
Q1 		$61 Buy
+10
New +$83 ﹤0.01% 747

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Vanguard National Trust's DNA Position: Q2 2026 in Review

Vanguard National Trust sold out of Ginkgo Bioworks (DNA) in Q2 2026, closing a stake of 10 shares — an estimated $61 sold.

Vanguard National Trust first reported a position in DNA in Q1 2026 and held it in 1 quarter. The position peaked at $61 in Q1 2026. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Vanguard National Trust reported no remaining Ginkgo Bioworks position as of Q2 2026 after selling out during the quarter.
  • Vanguard National Trust sold 10 Ginkgo Bioworks shares in Q2 2026, an estimated $61.
  • Vanguard National Trust first reported a position in Ginkgo Bioworks in Q1 2026 and held it in 1 quarter.
  • Vanguard National Trust's Ginkgo Bioworks position peaked at $61 in Q1 2026.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.